News Releases Home Synthetic Biology The History of Synthetic Biology Living Medicines Designing Synthetic Biotic™ Medicines Pipeline + Programs For Patients Our People Leadership Board of Directors Founders and Advisors Join Us Investors + Media Company Overview News & Events News Releases Event Calendar Presentations & Publications Stock Information Corporate Governance Financials Investor Resources Items Per Page 102550 Year None201920182017201620152014 November 12, 2018 Synlogic Presents Data at the 2018 Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD) November 7, 2018 Synlogic Announces Third Quarter 2018 Conference Call and Webcast November 6, 2018 Synlogic Presents Preclinical Data from First Synthetic BioticTM Clinical Candidate in Immuno-Oncology at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting November 1, 2018 Synlogic to Host Analyst & Investor Event at the Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting October 2, 2018 Synlogic Appoints Dr. Aoife Brennan as President and Chief Executive Officer September 25, 2018 Synlogic to Webcast Presentation at the Leerink Partners Roundtable Series: Rare Disease & Oncology September 4, 2018 Synlogic Reports Positive Interim Phase 1/2a Data Demonstrating Safety, Tolerability and Proof-of-Mechanism in Healthy Volunteers for SYNB1618, in Development for the Management of Phenylketonuria (PKU) August 29, 2018 Synlogic to Webcast Presentation at the H. C. Wainwright 20th Annual Global Investment Conference August 13, 2018 Synlogic Publishes Preclinical Data Supporting Development of SYNB1618, a Synthetic Biotic™ Medicine as a Potential Treatment for Phenylketonuria August 8, 2018 Synlogic Reports Second Quarter 2018 Financial Results and Provides Program Updates Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last » Displaying 31 - 40 of 94 Email Alerts Contact IR RSS Feeds Print Page Email Page
Items Per Page 102550 Year None201920182017201620152014 November 12, 2018 Synlogic Presents Data at the 2018 Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD) November 7, 2018 Synlogic Announces Third Quarter 2018 Conference Call and Webcast November 6, 2018 Synlogic Presents Preclinical Data from First Synthetic BioticTM Clinical Candidate in Immuno-Oncology at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting November 1, 2018 Synlogic to Host Analyst & Investor Event at the Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting October 2, 2018 Synlogic Appoints Dr. Aoife Brennan as President and Chief Executive Officer September 25, 2018 Synlogic to Webcast Presentation at the Leerink Partners Roundtable Series: Rare Disease & Oncology September 4, 2018 Synlogic Reports Positive Interim Phase 1/2a Data Demonstrating Safety, Tolerability and Proof-of-Mechanism in Healthy Volunteers for SYNB1618, in Development for the Management of Phenylketonuria (PKU) August 29, 2018 Synlogic to Webcast Presentation at the H. C. Wainwright 20th Annual Global Investment Conference August 13, 2018 Synlogic Publishes Preclinical Data Supporting Development of SYNB1618, a Synthetic Biotic™ Medicine as a Potential Treatment for Phenylketonuria August 8, 2018 Synlogic Reports Second Quarter 2018 Financial Results and Provides Program Updates Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last » Displaying 31 - 40 of 94
November 12, 2018 Synlogic Presents Data at the 2018 Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD)
November 6, 2018 Synlogic Presents Preclinical Data from First Synthetic BioticTM Clinical Candidate in Immuno-Oncology at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting
November 1, 2018 Synlogic to Host Analyst & Investor Event at the Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting
September 25, 2018 Synlogic to Webcast Presentation at the Leerink Partners Roundtable Series: Rare Disease & Oncology
September 4, 2018 Synlogic Reports Positive Interim Phase 1/2a Data Demonstrating Safety, Tolerability and Proof-of-Mechanism in Healthy Volunteers for SYNB1618, in Development for the Management of Phenylketonuria (PKU)
August 29, 2018 Synlogic to Webcast Presentation at the H. C. Wainwright 20th Annual Global Investment Conference
August 13, 2018 Synlogic Publishes Preclinical Data Supporting Development of SYNB1618, a Synthetic Biotic™ Medicine as a Potential Treatment for Phenylketonuria